NCT07049328Phase 1Recruiting
HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata
A Phase 1 Study of HCW9302, an IL-2 Fusion Protein, for Alopecia Areata
In the register
This trial is not attached to a programme in the register yet. Unattached trials are kept on purpose: they are where new programmes turn up first.
What the registry records
- Status
- Recruiting
- Declared phase
- Phase 1
- Sponsor
- HCW Biologics
- Participants (registry)
- 30
- Start
- August 2025
- Primary completion
- July 2027 (planned)
- Study completion
- December 2027 (planned)
- Last registry update
- September 2026
- Countries
- United States
Conditions studied: Alopecia Areata(AA)
Interventions: HCW9302, an IL-2 fusion protein
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.